Abcam, ab232664, Anti-ASGR2 antibody [EPR16974] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ASGR2 antibody. Carrier free. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16974,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232664 is the carrier-free version of
ab197032
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The asialoglycoprotein receptor 2 (ASGR2) sometimes called Ashwell receptor subunit 2 is a transmembrane protein with a mass of approximately 46 kDa. ASGR2 combines with a similar protein ASGR1 to form a functional receptor complex. It is mostly found in the liver playing an important role in endocytosis by binding galactose-terminated glycoproteins. The receptor facilitates the clearance of these glycoproteins from the bloodstream making the liver a major site for their catabolism.
Biological function summary
ASGR2 participates in regulating serum glycoprotein levels. It is part of the asialoglycoprotein receptor complex working with ASGR1 to internalize glycoproteins for lysosomal degradation. This process is important for maintaining homeostasis of serum proteins and influencing liver function. Its activity affects hepatocyte turnover and cellular response to extracellular stimuli within the liver.
Pathways
ASGR2 is involved in the endocytosis and trafficking pathways. These pathways guide the internalization and lysosomal degradation of serum glycoproteins. ASGR2's interaction with ASGR1 through these pathways highlights its role in glycoprotein metabolism. Additionally its function intersects with the complement system's mannose-binding protein affecting immune response by clearing immune complexes.
ASGR2's dysfunction correlates with liver conditions like congenital disorders of glycosylation and hepatitis B virus infection. In hepatitis B altered ASGR2 function affects virus binding and clearance. The asialoglycoprotein receptor complex including the ASGR1/ASGR2 interaction is central to understanding changes in liver pathology and therapeutic targeting of liver diseases.